Valuation: Actavis PLC

Market Cap 63.66B 57.09B 52.61B 47.78B 90.43B 5,969B 92.96B 630B 251B 3,198B 239B 234B 10,109B P/E 2018
-8.76x
P/E 2019 -11.9x
Enterprise Value 80.96B 72.61B 66.92B 60.77B 115B 7,591B 118B 801B 319B 4,067B 304B 297B 12,857B EV / Sales 2018
4.24x
EV / Sales 2019 4.98x
Free-Float
99.9%
Yield 2018
2.15%
Yield 2019 1.55%
Nov. 08 Allergan Aesthetics Announces Results from HARMONY IN DIVERSITY and HALO Phase 4 Studies of Aesthetic Treatment in Adults on GLP-1 Medications CI
Nov. 03 Allergan Aesthetics To Present New Research On Aesthetic Care Following Medical Weight Loss And Evolving Patient Needs At ASDS 2026 CI
Oct. 21 Allergan Aesthetics presents its latest scientific advances Zonebourse
Sep. 29 Abbvie Through Allergan Aesthetics Receives Health Canada Authorization for Boey for Frown Lines CI
Sep. 17 Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications CI
Sep. 15 Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies CI
Sep. 01 Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist CI
Apr. 07 Allergan Aesthetics Opens New Ami Training Center in Austin CI
Mar. 31 Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting CI
Mar. 30 Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting CI
Mar. 19 Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions CI
Mar. 04 Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients CI
Nov. 12 Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence CI
Manager TitleAgeSince
Director of Finance/CFO 56 2016-11-30
Director TitleAgeSince
Director/Board Member - 2020-05-07
Director/Board Member - 2020-05-07
Director/Board Member - 2020-05-07
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%+1.63%+48.17%+139.63% 1,276B
-0.47%+5.49%+49.03%+90.68% 676B
+0.20%+2.76%+34.37%+112.06% 519B
-0.66%+0.91%+38.38%+67.33% 388B
-0.48%+2.34%+70.66%+46.02% 365B
-1.04%-0.76%+28.02%+57.46% 307B
-0.17%-1.11%+2.99%+35.32% 287B
0.00%+0.86%+43.74%+74.04% 252B
+0.92%+2.03%+44.62%+125.07% 212B
Average -0.51%+2.34%+40.00%+83.07% 476B
Weighted average by Cap. -0.71%+2.51%+42.75%+96.56%

Financials

2018 2019
Net sales 15.79B 14.16B 13.05B 11.85B 22.43B 1,480B 23.05B 156B 62.25B 793B 59.25B 57.99B 2,507B 16.09B 14.43B 13.3B 12.08B 22.86B 1,508B 23.49B 159B 63.44B 808B 60.38B 59.1B 2,555B
Net income -5.1B -4.57B -4.21B -3.83B -7.24B -478B -7.44B -50.43B -20.09B -256B -19.13B -18.72B -809B -5.27B -4.73B -4.36B -3.96B -7.49B -494B -7.7B -52.16B -20.78B -265B -19.78B -19.36B -837B
Net Debt 21.89B 19.63B 18.09B 16.43B 31.1B 2,052B 31.96B 217B 86.31B 1,100B 82.15B 80.41B 3,476B 17.3B 15.52B 14.3B 12.99B 24.58B 1,622B 25.27B 171B 68.23B 869B 64.94B 63.56B 2,748B
Logo Actavis PLC
Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.
Employees
-